[{"id":"0a66098a-0a5e-43d0-a9e6-6aa16e1b7112","acronym":"ARST0531","url":"https://clinicaltrials.gov/study/NCT00354835","created_at":"2021-01-18T01:13:45.392Z","updated_at":"2024-07-02T16:35:56.665Z","phase":"Phase 3","brief_title":"Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma","source_id_and_acronym":"NCT00354835 - ARST0531","lead_sponsor":"Children's Oncology Group","biomarkers":" UGT1A1 • CYP2C9","pipe":" | ","alterations":" UGT1A1*1*1","tags":["UGT1A1 • CYP2C9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • irinotecan • vincristine • dactinomycin • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 481","initiation":"Initiation: 12/26/2006","start_date":" 12/26/2006","primary_txt":" Primary completion: 12/31/2014","primary_completion_date":" 12/31/2014","study_txt":" Completion: 12/31/2022","study_completion_date":" 12/31/2022","last_update_posted":"2023-01-31"},{"id":"6ca623a5-286e-409d-9261-12fcda2e9229","acronym":"","url":"https://clinicaltrials.gov/study/NCT01911728","created_at":"2021-01-18T08:37:05.884Z","updated_at":"2024-07-02T16:37:20.683Z","phase":"Phase 1","brief_title":"Drug-drug Interaction Study With MDV3100 and a Cocktail of Substrates","source_id_and_acronym":"NCT01911728","lead_sponsor":"Astellas Pharma Europe B.V.","biomarkers":" CYP2C9 • CYP3A4","pipe":"","alterations":" ","tags":["CYP2C9 • CYP3A4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • midazolam hydrochloride • omeprazole"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 07/25/2011","start_date":" 07/25/2011","primary_txt":" Primary completion: 02/21/2012","primary_completion_date":" 02/21/2012","study_txt":" Completion: 02/21/2012","study_completion_date":" 02/21/2012","last_update_posted":"2017-06-26"}]